ArticleScientific reports2025
DEFB4A/hBD2, a non-invasive serum biomarker for detection of ulcerative colitis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biosensor-Based Detection of Calprotectin and Lactoferrin as Neutrophil-Derived Markers of Inflammatory Bowel Diseases: From Molecular Pathophysiology to Point-of-Care Platforms.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ulcerative colitis (UC) is a chronic episodic relapsing, and remitting inflammatory bowel disease with increasing frequency worldwide. Along with colonoscopy, faecal calprotectin (FCP) > 150 µg/g, elevated faecal Lactoferrin or elevated CRP are now considered for diagnosis and to take treatment decision. But there are a group of patients showing either symptomatic remission with high biomarkers or active disease having no biomarker. Hence, identification of biomarker with better diagnostic potential is still required for UC patients. To determine the deregulated genes in UC, microarray analysis was employed with colonic tissue of UC and irritable bowel syndrome (IBS) as control. Pathway enrichment analysis with differentially expressed (DE) genes revealed anti-microbial peptide mediated immune response pathways might play pivotal role in UC. Subsequently, qRT-PCR validation depicted that among the DE genes, DefensinsB4A (DEFB4A/hBD2) showed highest significant alterations in UC compared to IBS control. The data was also validated by immunohistochemistry with colonic tissue from IBS and active UC, and subsequently ELISA with healthy control (HC), active UC, and UC in remission. Crohn’s disease patient was considered as other inflammatory disease. A significantly high level of DEFB4A/hBD2 was noted in the serum of active UC patients compared to HC (p < 0.001) and it was significantly reduced in patients in remission (p < 0.001). ROC analysis revealed that DEFB4A/hBD2 with more than 220.74 pg/ml level can differentiate active UC patient from HC and active UC from patients in remission with 89% and 90% sensitivity, and 95% and 77% specificity respectively. The positive predictive values were 85.4% and 83% respectively while negative predictive value was 79% in both and 95% confidence intervals were (0.88–0.98) and (0.81–0.97) respectively. These findings suggest that DEFB4A/hBD2 could serve as a potential serum diagnostic marker for active UC patients; a decrease in its level indicates remission, though further validation with a larger sample size is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.